Altered surface markers in lung cancer. Lack of cell-surface Fas/APO-1 expression in pulmonary adenocarcinoma may allow escape from immune surveillance.
Nambu
Yoshihiro
Y
Department of Internal Medicine, Division of Respiratory Diseases, Kanazawa Medical University, Ishikawa, Japan.
Beer
David G
DG
D000230:Adenocarcinoma / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000378:metabolism; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007124:Immunoenzyme Techniques; D007157:Immunologic Surveillance; D008175:Lung Neoplasms / Q000378:metabolism*; D016393:Lymphoma, B-Cell / Q000378:metabolism; D018613:Microscopy, Confocal; D009842:Oligopeptides; D010455:Peptides / Q000276:immunology; D014162:Transfection; D014407:Tumor Cells, Cultured; D019014:fas Receptor / Q000235:genetics / Q000378:metabolism*
D014408:Biomarkers, Tumor; D009842:Oligopeptides; D010455:Peptides; D019014:fas Receptor; C085706:FLAG peptide